根据EV-304研究数据,安斯泰来制药公司公布的最新结果显示,在围术期使用enfortumab vedotin联合帕博利珠单抗的治疗方案,其安全性特征与先前对该联合疗法的经验保持一致。
这一发现进一步支持了该联合治疗方案在临床应用中的安全性一致性,为后续治疗策略的制定提供了重要参考依据。
根据EV-304研究数据,安斯泰来制药公司公布的最新结果显示,在围术期使用enfortumab vedotin联合帕博利珠单抗的治疗方案,其安全性特征与先前对该联合疗法的经验保持一致。
这一发现进一步支持了该联合治疗方案在临床应用中的安全性一致性,为后续治疗策略的制定提供了重要参考依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.